No link found between asthma drugs, suicide attempts

July 4, 2012

(Medical Xpress) -- Treating asthma with leukotriene-modifying agents does not pose an increased risk of suicide in children, according to new research at the University of Illinois at Chicago College of Pharmacy.

UIC professor Glen Schumock began studying the link between suicide and the following a U.S. warning in 2008 saying it was reviewing reports of mood and behavior changes and suicidal tendencies among patients taking the drugs.

In a new study published in the Journal of Allergy and Clinical Immunology, Schumock and his research team found no evidence that LTMAs -- an oral treatment that works by blocking inflammation in the airways -- were attributed to suicide attempts.

Two prior studies conducted by Schumock, who also serves as director of UIC's Center for Pharmacoeconomic Research, cast doubts on the increased risk of suicide in those taking LTMAs, but "this was the first objective evidence to refute the association," he said.

The drugs include montelukast, known by its trade name Singulair, one of the 10 most prescribed pharmaceuticals in the U.S.; zafirlukast, marketed as Accolate; and zileuton, or Zyflo. Besides asthma, the drugs are also commonly used for .

After reviewing on the LTMA drugs in 2008, the FDA found no suicidal events, but they still issued a warning, Schumock said. Manufacturers were asked by the FDA in June 2009 to include a precaution in the drugs' prescribing information about reports of suicide and other .

Up until then, the number of LTMA prescriptions dispensed in the U.S. had increased substantially each year. Prescriptions rose from 6.9 million in 1999 to 27.8 million in 2007. However, following the FDA warning in 2008, the number of LTMA prescriptions decreased to 25.8 million, and 25.4 million the following year.

"The drugs could benefit patients, but naturally doctors may have been wary of using them because of the FDA warning," Schumock said. However, the warning was based solely on case reports, which do not prove there is a link between a and an adverse event because there can be so many other factors involved, he said.

An insurance claims database was the source of data for Schumock's study. He and his research team found 344 cases of attempted suicide from a group of 195,000 five- to 24-year-olds taking asthma medications.

According to the research, the suicidal group had increased rates of substance abuse, bipolar disease, depression, schizophrenia, and epilepsy, among other illnesses. The subjects also were being treated with additional medications such as antidepressants, antipsychotics, and anticonvulsants. After accounting for these factors, Schumock and his colleagues found no increased risk for suicide among those taking LTMAs compared to other asthma medications.

Among cases, 5.5 percent were using LTMAs at the time of their suicide attempt, compared with 6.5 percent who had not tried to commit suicide. All but five of the subjects were taking montelukast, with the remaining taking zafirlukast. No cases were reported using zileuton, Schumock said.

The research focused on children, adolescents, and young adults. In these patients LTMAs are an important treatment option because these medications can be taken orally, whereas other asthma drugs are inhaled and can be difficult for children to administer, he said.

"While there still needs to be additional research, physicians who treat kids with LTMAs may feel more comfortable now if there was any hesitation before," Schumock said.

Schumock said the research suggested an increased risk of in young adults ages 19 to 24 who used LTMAs, but the finding was not statistically significant. Further research needs to be conducted in that age group and in adults, he said.

Explore further: Antidepressant-suicide link in youths absent in new analysis

Related Stories

Antidepressant-suicide link in youths absent in new analysis

February 6, 2012

In 2004, concerns about antidepressant drugs increasing suicidal thoughts and behaviors in young patients prompted the FDA to issue a rare "black box warning." Now, a new analysis of clinical trial data finds that treatment ...

Recommended for you

Four gut bacteria decrease asthma risk in infants

September 30, 2015

New research by scientists at UBC and BC Children's Hospital finds that infants can be protected from getting asthma if they acquire four types of gut bacteria by three months of age. More than 300 families from across Canada ...

Flu infection reveals many paths to immune response

September 28, 2015

A new study of influenza infection in an animal model broadens understanding of how the immune system responds to flu virus, showing that the process is more dynamic than usually described, engaging a broader array of biological ...

Immune cells may help fight against obesity

September 15, 2015

While a healthy lifestyle and "good genes" are known to help prevent obesity, new research published on September 15 in Immunity indicates that certain aspects of the immune system may also play an important role. In the ...

The Achilles' heel of HIV

September 8, 2015

Researchers at the University of Bonn have discovered how cells in the body can detect the genetic material of so-called retroviruses. The pathogen of the immunodeficiency disease AIDS, the HI-1 virus, also belongs to this ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.